Pub Date : 2021-12-31DOI: 10.33696/cancerimmunol.3.057
Yenisey Triana Marrero, V. M. Suárez, Yaneisy Duarte Pérez, Gabriela Díaz Domínguez, Imilla, Casado Hernández, Elizabeth Hernández Ramos, R. M. Díaz, Consuelo Macías, Abraham
Yenisey Triana Marrero1*, Vianed Marsán Suárez2, Yaneisy Duarte Pérez3, Gabriela Díaz Domínguez4, Imilla Casado Hernández5, Elizabeth Hernández Ramos6, Rosa María Lam Díaz7, Consuelo Milagros Macías Abraham8 1Dra. in Medicine, First degree specialist in MGI and Immunology, Assistant teacher, Associate Researcher 2Dra. in Medical Sciences, Second Degree Specialist in Immunology. Professor and Senior Researcher 3Dra. in Medicine, First degree specialist in MGI and Immunology, Assistant teacher 4Degree in Biochemistry and Molecular Biology, Associate Researcher 5MsC. Licensed in biology. Assistant Professor, Associate Researcher 6Degree in Biochemistry and Molecular Biology 7Dra. in Medicine, First degree specialist in Biostatistics, Assistant Researcher 8Dra. in Medical Sciences, Second Degree Specialist in Immunology, Professor and Senior Researcher 1-8Department of Immunology, “José Manuel BallesterSantovenia” Institute of Hematology and Immunology, Calle 19 e / 8 y 10. Postal code 10400, Vedado, Havana, Cuba *Correspondence should be addressed to Yenisey Triana Marrero; yeniseyt@infomed.sld.cu
{"title":"Immunophenotypic Characterization by Flow Cytometry of Chronic Lymphoid Leukemia","authors":"Yenisey Triana Marrero, V. M. Suárez, Yaneisy Duarte Pérez, Gabriela Díaz Domínguez, Imilla, Casado Hernández, Elizabeth Hernández Ramos, R. M. Díaz, Consuelo Macías, Abraham","doi":"10.33696/cancerimmunol.3.057","DOIUrl":"https://doi.org/10.33696/cancerimmunol.3.057","url":null,"abstract":"Yenisey Triana Marrero1*, Vianed Marsán Suárez2, Yaneisy Duarte Pérez3, Gabriela Díaz Domínguez4, Imilla Casado Hernández5, Elizabeth Hernández Ramos6, Rosa María Lam Díaz7, Consuelo Milagros Macías Abraham8 1Dra. in Medicine, First degree specialist in MGI and Immunology, Assistant teacher, Associate Researcher 2Dra. in Medical Sciences, Second Degree Specialist in Immunology. Professor and Senior Researcher 3Dra. in Medicine, First degree specialist in MGI and Immunology, Assistant teacher 4Degree in Biochemistry and Molecular Biology, Associate Researcher 5MsC. Licensed in biology. Assistant Professor, Associate Researcher 6Degree in Biochemistry and Molecular Biology 7Dra. in Medicine, First degree specialist in Biostatistics, Assistant Researcher 8Dra. in Medical Sciences, Second Degree Specialist in Immunology, Professor and Senior Researcher 1-8Department of Immunology, “José Manuel BallesterSantovenia” Institute of Hematology and Immunology, Calle 19 e / 8 y 10. Postal code 10400, Vedado, Havana, Cuba *Correspondence should be addressed to Yenisey Triana Marrero; yeniseyt@infomed.sld.cu","PeriodicalId":73633,"journal":{"name":"Journal of cancer immunology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47641275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-31DOI: 10.33696/cancerimmunol.3.055
Pouya Safarzadeh Kozani, Pooria Safarzadeh Kozani, R. O’Connor
T cells to unique antigens, the T-cell activation in a major complex chimeric as of the antigen recognition moiety to a single-chain variable fragment domain (scFv) and it the ζ chain of the TCR/CD3 modular recombinant, the intracellular CD3 ζ to T-cell activation following antigen engagement. it the origin of the chimeric antigen receptors (CARs) used clinically to of this very that CD3 with CD3 or growth factor receptor-bound protein optimal structural reconfigurations
{"title":"Humanized Chimeric Antigen Receptor (CAR) T cells","authors":"Pouya Safarzadeh Kozani, Pooria Safarzadeh Kozani, R. O’Connor","doi":"10.33696/cancerimmunol.3.055","DOIUrl":"https://doi.org/10.33696/cancerimmunol.3.055","url":null,"abstract":"T cells to unique antigens, the T-cell activation in a major complex chimeric as of the antigen recognition moiety to a single-chain variable fragment domain (scFv) and it the ζ chain of the TCR/CD3 modular recombinant, the intracellular CD3 ζ to T-cell activation following antigen engagement. it the origin of the chimeric antigen receptors (CARs) used clinically to of this very that CD3 with CD3 or growth factor receptor-bound protein optimal structural reconfigurations","PeriodicalId":73633,"journal":{"name":"Journal of cancer immunology","volume":"3 1","pages":"183 - 187"},"PeriodicalIF":0.0,"publicationDate":"2021-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43558611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-31DOI: 10.33696/cancerimmunol.3.054
Lobna Abdel Aziz Kilany, M. Aboulwafa, H. Zedan
Lobna Abdel Aziz Kilany1, Mohammad Mabrouk Aboulwafa2,3*, Hamdallah Hafez Zedan4 1Central administration of pharmaceuticals, Egyptian Drug Authority, 21 Abdel-Aziz Al souad St, Manial, Cairo, Egypt 2Faculty of Pharmacy, King Salman International University, Ras-Sedr, South Sinai, Egypt 3Department of Microbiology and Immunology, Faculty of Pharmacy, Ain Shams University, African union organization Street, Abbassia, Cairo 11566, Egypt 4Department of Microbiology and Immunology, Faculty of Pharmacy, Cairo University, Kasr El-Aini St., Cairo 11562, Egypt *Correspondence should be addressed to Prof. Dr. Mohammad M. Aboulwafa; maboulwafa@yahoo.com, maboulwafa@pharma.asu. edu.eg, mohammad.aboulwafa@ksiu.edu.eg
Lobna Abdel Aziz Kilany1，Mohammad Mabrouk Aboulwafa2，3*，Hamdallah Hafez Zedan4埃及药品管理局中央药品管理局，埃及开罗Manial Abdel Aziza Al souad街21号2埃及西奈半岛南西奈Ras Sedr萨勒曼国王国际大学药学院3艾因沙姆斯大学药学院微生物学和免疫学系，非洲联盟组织Street，Abbassia，开罗11566，埃及4开罗大学药学院微生物学和免疫学系，Kasr El Aini St.，开罗11562，埃及*应致函Mohammad M.Aboulwafa教授博士；maboulwafa@yahoo.com，maboulwafa@pharma.asu.例如，mohammad.aboulwafa@ksiu.edu.eg
{"title":"Therapeutic Monoclonal Antibodies: Future Prospectives","authors":"Lobna Abdel Aziz Kilany, M. Aboulwafa, H. Zedan","doi":"10.33696/cancerimmunol.3.054","DOIUrl":"https://doi.org/10.33696/cancerimmunol.3.054","url":null,"abstract":"Lobna Abdel Aziz Kilany1, Mohammad Mabrouk Aboulwafa2,3*, Hamdallah Hafez Zedan4 1Central administration of pharmaceuticals, Egyptian Drug Authority, 21 Abdel-Aziz Al souad St, Manial, Cairo, Egypt 2Faculty of Pharmacy, King Salman International University, Ras-Sedr, South Sinai, Egypt 3Department of Microbiology and Immunology, Faculty of Pharmacy, Ain Shams University, African union organization Street, Abbassia, Cairo 11566, Egypt 4Department of Microbiology and Immunology, Faculty of Pharmacy, Cairo University, Kasr El-Aini St., Cairo 11562, Egypt *Correspondence should be addressed to Prof. Dr. Mohammad M. Aboulwafa; maboulwafa@yahoo.com, maboulwafa@pharma.asu. edu.eg, mohammad.aboulwafa@ksiu.edu.eg","PeriodicalId":73633,"journal":{"name":"Journal of cancer immunology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45039284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-05DOI: 10.33696/cancerimmunol.3.049
Taylor J. Ellison, B. Jurgielewicz, S. Stice, Yao Yao
Nanomedicine, which includes nanoparticles and other nanomaterials for diagnosis and therapeutic delivery to treat numerous diseases, is making advances [1]. Utilizing engineered nanomaterials as delivery shuttles for therapeutics provides an opportunity to increase targeting specificity for treatments of certain disorders, as well as provide intrinsic benefits to cell systems of interest [2,3]. However, it is important to understand the functional properties of materials in pre-clinical studies. Proper selection of nanomaterials could be enhanced by recent studies in the field of cellular uptake of nanomaterials. The study of EVs is an expanding field within nanomedicine and are one such example of nanomaterials as a drug delivery shuttle. EVs are lipid-bound vesicles ranging in size from 40-1000 nm that mediate intercellular communication through shuttling nucleic acids, protein and lipids between cells. Once thought to be the secreted waste of cells, EVs have been engineered as drug delivery vectors due to multiple intrinsic benefits such as biocompatibility of genetic materials, therapeutic potentials, low immunogenicity and toxicity, ability to cross bio-barriers and for repeated dosing, various routes of administration [4-6]. Previous work from our group and others indicates that the therapeutic potential and Abstract
{"title":"Quantifying Neural Stem Cell-Derived Extracellular Vesicle Uptake Using Imaging Flow Cytometry","authors":"Taylor J. Ellison, B. Jurgielewicz, S. Stice, Yao Yao","doi":"10.33696/cancerimmunol.3.049","DOIUrl":"https://doi.org/10.33696/cancerimmunol.3.049","url":null,"abstract":"Nanomedicine, which includes nanoparticles and other nanomaterials for diagnosis and therapeutic delivery to treat numerous diseases, is making advances [1]. Utilizing engineered nanomaterials as delivery shuttles for therapeutics provides an opportunity to increase targeting specificity for treatments of certain disorders, as well as provide intrinsic benefits to cell systems of interest [2,3]. However, it is important to understand the functional properties of materials in pre-clinical studies. Proper selection of nanomaterials could be enhanced by recent studies in the field of cellular uptake of nanomaterials. The study of EVs is an expanding field within nanomedicine and are one such example of nanomaterials as a drug delivery shuttle. EVs are lipid-bound vesicles ranging in size from 40-1000 nm that mediate intercellular communication through shuttling nucleic acids, protein and lipids between cells. Once thought to be the secreted waste of cells, EVs have been engineered as drug delivery vectors due to multiple intrinsic benefits such as biocompatibility of genetic materials, therapeutic potentials, low immunogenicity and toxicity, ability to cross bio-barriers and for repeated dosing, various routes of administration [4-6]. Previous work from our group and others indicates that the therapeutic potential and Abstract","PeriodicalId":73633,"journal":{"name":"Journal of cancer immunology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44974744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-05DOI: 10.33696/cancerimmunol.3.051
Wendy J. Sherman
Less than 5% of glioblastomas result from a hereditary syndrome. While not common, they do occur and perhaps may be under-recognized if family history is not known. Now, with more frequent germline testing done as a component of next generation tumor sequencing, it is hypothesized that these hereditary syndromes are better detected. This improved detection is not only beneficial for screening family members and screening the patient for other associated malignancies, but this opens up an opportunity for us as clinicians and scientists to better understand the tumorigenesis of glioblastoma in hereditary syndromes, which in turn may offer individualized treatment regimens.
{"title":"Anti-PD1 Therapy in Lynch Syndrome-associated Recurrent Glioblastoma","authors":"Wendy J. Sherman","doi":"10.33696/cancerimmunol.3.051","DOIUrl":"https://doi.org/10.33696/cancerimmunol.3.051","url":null,"abstract":"Less than 5% of glioblastomas result from a hereditary syndrome. While not common, they do occur and perhaps may be under-recognized if family history is not known. Now, with more frequent germline testing done as a component of next generation tumor sequencing, it is hypothesized that these hereditary syndromes are better detected. This improved detection is not only beneficial for screening family members and screening the patient for other associated malignancies, but this opens up an opportunity for us as clinicians and scientists to better understand the tumorigenesis of glioblastoma in hereditary syndromes, which in turn may offer individualized treatment regimens.","PeriodicalId":73633,"journal":{"name":"Journal of cancer immunology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46901859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-05DOI: 10.33696/cancerimmunol.3.050
K. Benihoud, C. Brenner
Although being a complex pathology with genetic as well as non-genetic etiologies, cancer is characterized by a limited series of hallmarks including energetic metabolism reprogramming [1]. Long ago O. Warburg unraveled a bias of tumor metabolism in favor of glycolysis, the socalled Warburg effect. Indeed, tumor cells display both an increase in glucose uptake and fermentation of glucose to lactate [2]. Since these pioneering works, different alterations of tumor metabolism were reported such as deregulated uptake of glutamine or new modes of nutrient acquisition [3]. In general, cancer cells exhibit a high rate of proliferation due to constitutive anabolism and catabolism activation. Moreover, by competing for nutrients, inducing hypoxia and releasing inhibitory molecules in tumor microenvironment (TME), tumors dramatically affect immune cell metabolism [4].
{"title":"Profiling the Energy Metabolism at the Cell Subpopulation Level","authors":"K. Benihoud, C. Brenner","doi":"10.33696/cancerimmunol.3.050","DOIUrl":"https://doi.org/10.33696/cancerimmunol.3.050","url":null,"abstract":"Although being a complex pathology with genetic as well as non-genetic etiologies, cancer is characterized by a limited series of hallmarks including energetic metabolism reprogramming [1]. Long ago O. Warburg unraveled a bias of tumor metabolism in favor of glycolysis, the socalled Warburg effect. Indeed, tumor cells display both an increase in glucose uptake and fermentation of glucose to lactate [2]. Since these pioneering works, different alterations of tumor metabolism were reported such as deregulated uptake of glutamine or new modes of nutrient acquisition [3]. In general, cancer cells exhibit a high rate of proliferation due to constitutive anabolism and catabolism activation. Moreover, by competing for nutrients, inducing hypoxia and releasing inhibitory molecules in tumor microenvironment (TME), tumors dramatically affect immune cell metabolism [4].","PeriodicalId":73633,"journal":{"name":"Journal of cancer immunology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44907511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-10-27DOI: 10.33696/cancerimmunol.3.052
Lydia Lichtiger, Janelle A. Rivera, Debashish Sahay, Rachel L. Miller
Breast cancer risk remains incompletely explained, and higher incidence rates of breast cancer over recent times and in urban and industrialized areas suggest environmental causes. Polycyclic aromatic hydrocarbons (PAH) are ubiquitous in the environment and epidemiological and rodent studies have shown associations between exposure to PAH and breast cancer incidence as well as mammary tumorigenesis. In addition, in vitro and rodent studies have implicated alterations in estrogen receptor alpha (Erα) signaling pathways following PAH exposure in limited experimental studies. However, our understanding of these mechanisms is incomplete. Sahay et al. addressed this gap by examining the effect of PAH exposure on epigenetic and transcriptional regulation of genes in the Erα pathway in a mouse cohort exposed to aerosolized PAH at proportions measured in urban air. In addition to alterations in the Erα signaling pathway in the pregnant mice and in their offspring and grandoffspring, the investigators observed higher body weights in mice exposed to PAH compared to the control. Given that associations between mammary tissue adiposity, systemic adiposity, and breast cancer risk have been observed previously, the finding of higher body weight in the PAH exposure group raises the possibility that body weight might influence the association between PAH exposure and breast cancer risk. Along with new analyses, we discuss the possibility that body weight may modify the association between PAH exposure, mammary cellular proliferation, and mammary gland ductal hyperplasia in offspring and grandoffspring mice and future research that may be needed to delineate these associations.
{"title":"Polycyclic Aromatic Hydrocarbons and Mammary Cancer Risk: Does Obesity Matter too?","authors":"Lydia Lichtiger, Janelle A. Rivera, Debashish Sahay, Rachel L. Miller","doi":"10.33696/cancerimmunol.3.052","DOIUrl":"https://doi.org/10.33696/cancerimmunol.3.052","url":null,"abstract":"Breast cancer risk remains incompletely explained, and higher incidence rates of breast cancer over recent times and in urban and industrialized areas suggest environmental causes. Polycyclic aromatic hydrocarbons (PAH) are ubiquitous in the environment and epidemiological and rodent studies have shown associations between exposure to PAH and breast cancer incidence as well as mammary tumorigenesis. In addition, in vitro and rodent studies have implicated alterations in estrogen receptor alpha (Erα) signaling pathways following PAH exposure in limited experimental studies. However, our understanding of these mechanisms is incomplete. Sahay et al. addressed this gap by examining the effect of PAH exposure on epigenetic and transcriptional regulation of genes in the Erα pathway in a mouse cohort exposed to aerosolized PAH at proportions measured in urban air. In addition to alterations in the Erα signaling pathway in the pregnant mice and in their offspring and grandoffspring, the investigators observed higher body weights in mice exposed to PAH compared to the control. Given that associations between mammary tissue adiposity, systemic adiposity, and breast cancer risk have been observed previously, the finding of higher body weight in the PAH exposure group raises the possibility that body weight might influence the association between PAH exposure and breast cancer risk. Along with new analyses, we discuss the possibility that body weight may modify the association between PAH exposure, mammary cellular proliferation, and mammary gland ductal hyperplasia in offspring and grandoffspring mice and future research that may be needed to delineate these associations.","PeriodicalId":73633,"journal":{"name":"Journal of cancer immunology","volume":"3 1","pages":"154 - 162"},"PeriodicalIF":0.0,"publicationDate":"2021-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42372088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-06-30DOI: 10.33696/cancerimmunol.3.046
A. Dumond, Gilles Pagès
{"title":"Relevance of Neuropilin 1 and Neuropilin 2 Targeting for Cancer Treatment","authors":"A. Dumond, Gilles Pagès","doi":"10.33696/cancerimmunol.3.046","DOIUrl":"https://doi.org/10.33696/cancerimmunol.3.046","url":null,"abstract":"","PeriodicalId":73633,"journal":{"name":"Journal of cancer immunology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46783448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-06-30DOI: 10.33696/cancerimmunol.3.045
Yoo Jane Han, Michaela U. Gack, O. Olopade
Tumor immunity and immunotherapy have become increasingly important in treatment strategies for a variety of malignancies including advanced triple negative breast cancer [1,2]. Although immunotherapy has been shown to be effective, patient response rates vary significantly and only a small fraction of patients respond favorably to the treatment [3]. The efficacy of cancer immunotherapy appears to depend on the host immune system recognizing and eliminating cancer cells [4]. Increasing evidence demonstrates a positive correlation between the presence of host antitumor immune responses and favorable patient outcomes for many cancers [5-8]. As an example, tumors with a high density of tumor-infiltrating lymphoid cells (TILs) in the tumor microenvironment are more likely to respond to immune checkpoint inhibitors, whereas those with low or no TILs are less likely to respond to the inhibitors [9-11]. Thus, interventions that render nonresponding tumors to become responding tumors and hence promote antitumor immunity bear tremendous therapeutic potential.
{"title":"Emerging Roles of Pseudogene RNAs in Antitumor and Antiviral Immunity","authors":"Yoo Jane Han, Michaela U. Gack, O. Olopade","doi":"10.33696/cancerimmunol.3.045","DOIUrl":"https://doi.org/10.33696/cancerimmunol.3.045","url":null,"abstract":"Tumor immunity and immunotherapy have become increasingly important in treatment strategies for a variety of malignancies including advanced triple negative breast cancer [1,2]. Although immunotherapy has been shown to be effective, patient response rates vary significantly and only a small fraction of patients respond favorably to the treatment [3]. The efficacy of cancer immunotherapy appears to depend on the host immune system recognizing and eliminating cancer cells [4]. Increasing evidence demonstrates a positive correlation between the presence of host antitumor immune responses and favorable patient outcomes for many cancers [5-8]. As an example, tumors with a high density of tumor-infiltrating lymphoid cells (TILs) in the tumor microenvironment are more likely to respond to immune checkpoint inhibitors, whereas those with low or no TILs are less likely to respond to the inhibitors [9-11]. Thus, interventions that render nonresponding tumors to become responding tumors and hence promote antitumor immunity bear tremendous therapeutic potential.","PeriodicalId":73633,"journal":{"name":"Journal of cancer immunology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41779899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-06-30DOI: 10.33696/cancerimmunol.3.048
F. Hadi, T. Maqbool, Saira Aftab, Muhammad Tahir, S. Ramzan, K. Kiran, A. Malik, S. Akhtar
Faheem Hadi1, Tahir Maqbool1, Saira Aftab1, Muhammad Tahir1, Shazia Ramzan2, Komal Kiran3, Arif Malik1, Shabana Akhtar1,4* 1Institute of Molecular Biology and Biotechnology, University of Lahore, Lahore, Pakistan 2Allama Iqbal Medical College Lahore, Lahore, Pakistan 3Services Hospital, Lahore, Pakistan 4School of Medical Sciences, University of Bradford, Bradford, UK *Correspondence should be addressed to Shabana Akhtar; s.akhtar133@bradford.ac.uk, shabana.akhtar@imbb.uol.edu.pk
Faheem Hadi1, Tahir Maqbool1, Saira Aftab1, Muhammad Tahir1, Shazia Ramzan2, Komal Kiran3, Arif mali1, Shabana Akhtar1,4* 1巴基斯坦拉合尔拉合尔大学分子生物学与生物技术研究所2巴基斯坦拉合尔allama Iqbal医学院拉合尔服务医院拉合尔英国布拉德福德大学医学学院*通信地址:Shabana Akhtar;s.akhtar133@bradford.ac.uk, shabana.akhtar@imbb.uol.edu.pk
{"title":"Dose-dependent Effects of Vitamin C on Cancer Regulation: A Review","authors":"F. Hadi, T. Maqbool, Saira Aftab, Muhammad Tahir, S. Ramzan, K. Kiran, A. Malik, S. Akhtar","doi":"10.33696/cancerimmunol.3.048","DOIUrl":"https://doi.org/10.33696/cancerimmunol.3.048","url":null,"abstract":"Faheem Hadi1, Tahir Maqbool1, Saira Aftab1, Muhammad Tahir1, Shazia Ramzan2, Komal Kiran3, Arif Malik1, Shabana Akhtar1,4* 1Institute of Molecular Biology and Biotechnology, University of Lahore, Lahore, Pakistan 2Allama Iqbal Medical College Lahore, Lahore, Pakistan 3Services Hospital, Lahore, Pakistan 4School of Medical Sciences, University of Bradford, Bradford, UK *Correspondence should be addressed to Shabana Akhtar; s.akhtar133@bradford.ac.uk, shabana.akhtar@imbb.uol.edu.pk","PeriodicalId":73633,"journal":{"name":"Journal of cancer immunology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45097196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：